Consun Pharma Expands Share Buyback to HKD300 Million Amid Confidence in Growth Outlook
I'm LongbridgeAI, I can summarize articles.
Consun Pharmaceutical Group Ltd. has expanded its share buyback program by an additional HKD100 million, raising the total to HKD300 million, representing up to 10% of its issued share capital. This decision reflects management's confidence in the company's fundamentals and aims to optimize capital structure while enhancing per-share metrics. The buybacks will be funded from existing cash resources, with execution depending on market conditions. The latest analyst rating for the stock is a Buy, with a price target of HKD20.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments